Paper Alert!! Our collaborative work with Giger Lab at UMich is out now in #ScienceTranslationMedicine Deletion of murine Sarm1 results in a microenvironment that delays peripheral nerve regeneration after injury | Science Translational Medicine @science.org
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Deletion of murine Sarm1 results in a microenvironment that delays peripheral nerve regeneration after injury
In Sarm1-deficient mice, peripheral nervous system regeneration is delayed after injury.
www.science.org
October 8, 2025 at 6:22 PM
Paper Alert!! Our collaborative work with Giger Lab at UMich is out now in #ScienceTranslationMedicine Deletion of murine Sarm1 results in a microenvironment that delays peripheral nerve regeneration after injury | Science Translational Medicine @science.org
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Check out our paper in this weeks issue: www.science.org/doi/10.1126/...
Dual roles of Sarm1 in the injury response. 👀 read on for more!
Dual roles of Sarm1 in the injury response. 👀 read on for more!
October 8, 2025 at 10:42 PM
Check out our paper in this weeks issue: www.science.org/doi/10.1126/...
Dual roles of Sarm1 in the injury response. 👀 read on for more!
Dual roles of Sarm1 in the injury response. 👀 read on for more!
In this review @Andrea-Loreto.bsky.social and I discuss the breadth of therapeutic potential for the neurodegenerative enzyme SARM1
- Challenges for SARM1 therapeutic inhibition
- SARM1 in non-neuronal cells
- SARM1 activation for selective peripheral neuroablation.
www.cell.com/trends/pharm...
- Challenges for SARM1 therapeutic inhibition
- SARM1 in non-neuronal cells
- SARM1 activation for selective peripheral neuroablation.
www.cell.com/trends/pharm...
Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation
Sterile alpha and TIR motif-containing protein 1 (SARM1),is a central enzyme that
drives programmed axon degeneration and has gathered significant interest as a therapeutic
target. Despite preclinical...
www.cell.com
October 21, 2025 at 6:16 AM
In this review @Andrea-Loreto.bsky.social and I discuss the breadth of therapeutic potential for the neurodegenerative enzyme SARM1
- Challenges for SARM1 therapeutic inhibition
- SARM1 in non-neuronal cells
- SARM1 activation for selective peripheral neuroablation.
www.cell.com/trends/pharm...
- Challenges for SARM1 therapeutic inhibition
- SARM1 in non-neuronal cells
- SARM1 activation for selective peripheral neuroablation.
www.cell.com/trends/pharm...
Our latest review with @doctorpaf.bsky.social! We discuss the breadth of therapeutic potential for the neurodegenerative enzyme SARM1.
-Challenges for SARM1 inhibition for neuroprotection
-Roles in non-neuronal cells
-SARM1 activation for selective peripheral neuroablation
dlvr.it/TNnCBh
-Challenges for SARM1 inhibition for neuroprotection
-Roles in non-neuronal cells
-SARM1 activation for selective peripheral neuroablation
dlvr.it/TNnCBh
October 21, 2025 at 5:44 AM
Our latest review with @doctorpaf.bsky.social! We discuss the breadth of therapeutic potential for the neurodegenerative enzyme SARM1.
-Challenges for SARM1 inhibition for neuroprotection
-Roles in non-neuronal cells
-SARM1 activation for selective peripheral neuroablation
dlvr.it/TNnCBh
-Challenges for SARM1 inhibition for neuroprotection
-Roles in non-neuronal cells
-SARM1 activation for selective peripheral neuroablation
dlvr.it/TNnCBh
Funded PhD at the University of Cambridge: design new SARM1 variants to study programmed axon death in neurodegeneration. Open to UK & international applicants
www.dementiaresearcher.nihr.ac.uk/job/phd-prog...
www.dementiaresearcher.nihr.ac.uk/job/phd-prog...
PhD: Mechanism of Programmed Axon Death
Funded PhD at the University of Cambridge: design new SARM1 variants to study programmed axon death in neurodegeneration. Open to UK & international applicants
www.dementiaresearcher.nihr.ac.uk
September 27, 2026 at 8:46 AM
Funded PhD at the University of Cambridge: design new SARM1 variants to study programmed axon death in neurodegeneration. Open to UK & international applicants
www.dementiaresearcher.nihr.ac.uk/job/phd-prog...
www.dementiaresearcher.nihr.ac.uk/job/phd-prog...
SARM1 senses dsDNA to promote NAD+ degradation and cell death @cellcellpress.bsky.social
www.cell.com/cell/fulltex...
www.cell.com/cell/fulltex...
October 28, 2025 at 2:39 AM
SARM1 senses dsDNA to promote NAD+ degradation and cell death @cellcellpress.bsky.social
www.cell.com/cell/fulltex...
www.cell.com/cell/fulltex...
SARM1 executes neuronal parthanatos and promotes excitotoxic cell death
www.cell.com/neuron/fullt...
www.cell.com/neuron/fullt...
April 16, 2026 at 2:44 PM
SARM1 executes neuronal parthanatos and promotes excitotoxic cell death
www.cell.com/neuron/fullt...
www.cell.com/neuron/fullt...
🚨 New pre-print! If you are interested in new roles for SARM1, check this out. The lab did cool work showing macrophages need Sarm1 to efficiently respond to immunoogical stimuli and PNS injury. Cell specific sarm1 KO mice give surprising results- check it out!
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
www.biorxiv.org
April 10, 2026 at 11:36 AM
🚨 New pre-print! If you are interested in new roles for SARM1, check this out. The lab did cool work showing macrophages need Sarm1 to efficiently respond to immunoogical stimuli and PNS injury. Cell specific sarm1 KO mice give surprising results- check it out!
www.biorxiv.org/content/10.6...
www.biorxiv.org/content/10.6...
'Skeetorial' of our latest paper: link.springer.com/article/10.1...
So proud of first author Christina Antoniou for this, now a postdoc with @melissa-gammons1.bsky.social.
(1) NMNAT2 is a repressor of SARM1 NADase in axons. A few people have NMNAT2 LoF mutations. Many more have low expression.
So proud of first author Christina Antoniou for this, now a postdoc with @melissa-gammons1.bsky.social.
(1) NMNAT2 is a repressor of SARM1 NADase in axons. A few people have NMNAT2 LoF mutations. Many more have low expression.
November 24, 2024 at 12:18 PM
'Skeetorial' of our latest paper: link.springer.com/article/10.1...
So proud of first author Christina Antoniou for this, now a postdoc with @melissa-gammons1.bsky.social.
(1) NMNAT2 is a repressor of SARM1 NADase in axons. A few people have NMNAT2 LoF mutations. Many more have low expression.
So proud of first author Christina Antoniou for this, now a postdoc with @melissa-gammons1.bsky.social.
(1) NMNAT2 is a repressor of SARM1 NADase in axons. A few people have NMNAT2 LoF mutations. Many more have low expression.
SARM1 inhibition protects neurons in FUS-ALS, Parkinson’s & excitotoxicity models. Will be exciting to see trials for these inhibitors in an expanding spectrum of neurodegeneration. Amazing therapeutic potential from inhibiting a protein originally found in a Drosophila mutant screen.
SARM1 executes neuronal parthanatos and promotes excitotoxic cell death
Wu et al. show that PARP1 hyperactivation activates the NAD⁺ hydrolase SARM1 to execute
neuronal parthanatos. SARM1 drives mitochondrial depolarization, AIF translocation,
and neuronal death following...
www.cell.com
April 22, 2026 at 9:35 AM
SARM1 inhibition protects neurons in FUS-ALS, Parkinson’s & excitotoxicity models. Will be exciting to see trials for these inhibitors in an expanding spectrum of neurodegeneration. Amazing therapeutic potential from inhibiting a protein originally found in a Drosophila mutant screen.
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
September 27, 2026 at 9:15 PM
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
September 27, 2026 at 9:15 PM
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
September 28, 2026 at 1:01 AM
Breaking the link between demyelination and axon loss: SARM1 inhibition as a neuroprotective strategy for multiple sclerosis #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
https://www.biorxiv.org/content/10.64898/2026.09.25.754536v1
NAD+ reduction in glutamatergic neurons triggers fatty acid catabolism and neuroinflammation in the brain, mitigated by SARM1 deletion #NeuroDegeneration
NAD+ reduction in glutamatergic neurons triggers fatty acid catabolism and neuroinflammation in the brain, mitigated by SARM1 deletion #NeuroDegeneration 🧪🧠
https://www.biorxiv.org/content/10.1101/2025.05.05.652246v1
https://www.biorxiv.org/content/10.1101/2025.05.05.652246v1
May 10, 2025 at 10:12 AM
NAD+ reduction in glutamatergic neurons triggers fatty acid catabolism and neuroinflammation in the brain, mitigated by SARM1 deletion #NeuroDegeneration
Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation: Trends in Pharmacological Sciences www.cell.com/trends/pharm...
Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation
Sterile alpha and TIR motif-containing protein 1 (SARM1),is a central enzyme that
drives programmed axon degeneration and has gathered significant interest as a therapeutic
target. Despite preclinical...
www.cell.com
October 21, 2025 at 6:49 AM
Targeting SARM1: from inhibition for neuroprotection to activation for neuroablation: Trends in Pharmacological Sciences www.cell.com/trends/pharm...
Now online! SARM1 senses dsDNA to promote NAD+ degradation and cell death
SARM1 senses dsDNA to promote NAD+ degradation and cell death
Detection of DNA is a fundamental strategy for life to recognize non-self or abnormal-self. This study uncovers that a protein known to mediate axon degeneration, SARM1, senses DNA to trigger downstream responses, including NAD+ degradation and cell death.
dlvr.it
October 24, 2025 at 6:52 PM
Now online! SARM1 senses dsDNA to promote NAD+ degradation and cell death
A recent @cp-cell.bsky.social paper proposed that double-stranded DNA directly binds and activates SARM1. In a new @pnas.org paper, an international team was unable to reproduce that central finding www.pnas.org/doi/abs/10.1...
Direct activation of SARM1 by dsDNA is not supported by biochemical and cellular evidence | PNAS
Sterile alpha and Toll/interleukin-1 receptor motif–containing protein 1 (SARM1) is
a NAD+-consuming enzyme that drives axon degeneration and is ac...
www.pnas.org
September 15, 2026 at 7:17 AM
A recent @cp-cell.bsky.social paper proposed that double-stranded DNA directly binds and activates SARM1. In a new @pnas.org paper, an international team was unable to reproduce that central finding www.pnas.org/doi/abs/10.1...
METTL1-mediated m7G modification enhances macrophage proinflammatory responses by promoting SARM1-induced NAD+ decline @sciimmunology.bsky.social
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
September 5, 2025 at 8:04 PM
METTL1-mediated m7G modification enhances macrophage proinflammatory responses by promoting SARM1-induced NAD+ decline @sciimmunology.bsky.social
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
C1q activates the mitochondrial enzyme SARM1, driving NAD⁺ cleavage into cADPR, which precipitates metabolic collapse and PANoptosis of homeostatic macrophages, amplifing autoimmune tissue inflammation @ImmunityCP @Stanford
www.cell.com/immunity/ful...
www.cell.com/immunity/ful...
March 8, 2026 at 2:55 AM
C1q activates the mitochondrial enzyme SARM1, driving NAD⁺ cleavage into cADPR, which precipitates metabolic collapse and PANoptosis of homeostatic macrophages, amplifing autoimmune tissue inflammation @ImmunityCP @Stanford
www.cell.com/immunity/ful...
www.cell.com/immunity/ful...
#TuesdayReads:
The @WadeMartinsLab shows how antisense oligonucleotides targeting SARM1 protect human neurons from axon degeneration—highlighting a promising therapeutic approach for neurodegenerative disease.
🔗 www.sciencedirect.com/science/arti...
The @WadeMartinsLab shows how antisense oligonucleotides targeting SARM1 protect human neurons from axon degeneration—highlighting a promising therapeutic approach for neurodegenerative disease.
🔗 www.sciencedirect.com/science/arti...
SARM1 activation induces reversible mitochondrial dysfunction and can be prevented in human neurons by antisense oligonucleotides
SARM1 is a key regulator of a conserved program of axon degeneration increasingly linked to human neurodegenerative diseases. Pathological SARM1 activ…
www.sciencedirect.com
July 15, 2025 at 12:20 PM
#TuesdayReads:
The @WadeMartinsLab shows how antisense oligonucleotides targeting SARM1 protect human neurons from axon degeneration—highlighting a promising therapeutic approach for neurodegenerative disease.
🔗 www.sciencedirect.com/science/arti...
The @WadeMartinsLab shows how antisense oligonucleotides targeting SARM1 protect human neurons from axon degeneration—highlighting a promising therapeutic approach for neurodegenerative disease.
🔗 www.sciencedirect.com/science/arti...
Pharmaceutical companies are beginning to test the therapeutic hypothesis that blocking SARM1 could save neurons that would otherwise be doomed to die.
#chemsky 🧪
#chemsky 🧪
SARM1 inhibitors enter clinical trials for ALS, neuropathy
Blocking the NAD hydrolase may save axons from neurodegeneration, if researchers can figure out a safe way to do it
cen.acs.org
June 25, 2026 at 12:19 PM
Pharmaceutical companies are beginning to test the therapeutic hypothesis that blocking SARM1 could save neurons that would otherwise be doomed to die.
#chemsky 🧪
#chemsky 🧪
Delighted to announce the latest preprint from our amazing team: www.biorxiv.org/content/10.6...
Laura Carlton and Emma Wilson report luciferase mapping of the human NMNAT2 and SARM1 promoters, naturally-occurring human gene variants within them and their functional consequences.
1/5
Laura Carlton and Emma Wilson report luciferase mapping of the human NMNAT2 and SARM1 promoters, naturally-occurring human gene variants within them and their functional consequences.
1/5
April 12, 2026 at 8:29 PM
Delighted to announce the latest preprint from our amazing team: www.biorxiv.org/content/10.6...
Laura Carlton and Emma Wilson report luciferase mapping of the human NMNAT2 and SARM1 promoters, naturally-occurring human gene variants within them and their functional consequences.
1/5
Laura Carlton and Emma Wilson report luciferase mapping of the human NMNAT2 and SARM1 promoters, naturally-occurring human gene variants within them and their functional consequences.
1/5
So SARM1 is required for more than killing axons
SARM1 is required for macrophage immunophenotype switching that is essential for nerve repair https://www.biorxiv.org/content/10.64898/2026.04.07.716973v1
April 10, 2026 at 8:51 AM
So SARM1 is required for more than killing axons
I’m Michael Coleman, working in Cambridge, UK on how nerve injury, and some gene mutations, toxins & viruses kill axons through the NMNAT2-SARM1 pathway, how to block this & which human diseases and specific patients it would be most useful to block it in.
Really appreciate this to rebuild networks!
Really appreciate this to rebuild networks!
Science on Bluesky is growing rapidly!
Science friends, introduce yourselves below and I’ll share! Who are you? What do you work on? Where are you based?
I’ll go first. I’m David, and I study sharks and their conservation. I’m based in the Washington, DC area.
🧪🦑🌎🦈🐡
Science friends, introduce yourselves below and I’ll share! Who are you? What do you work on? Where are you based?
I’ll go first. I’m David, and I study sharks and their conservation. I’m based in the Washington, DC area.
🧪🦑🌎🦈🐡
October 22, 2023 at 3:30 PM
I’m Michael Coleman, working in Cambridge, UK on how nerve injury, and some gene mutations, toxins & viruses kill axons through the NMNAT2-SARM1 pathway, how to block this & which human diseases and specific patients it would be most useful to block it in.
Really appreciate this to rebuild networks!
Really appreciate this to rebuild networks!